LL-37 Peptide
PEPTIDES+ MEMBERS ONLY
INDICATIONS FOR USE
LL-37 is a synthetic version of a naturally occurring antimicrobial peptide (AMP) in the human innate immune system. It is used off-label to enhance immune defense, treat chronic infections, and reduce inflammation. It is also explored for its role in wound healing, autoimmune disorders, and biofilm disruption in resistant bacterial infections.
ROUTE OF ADMINISTRATION
Topical: Applied directly to the skin or scalp as a cream, serum, or gel.
Injectable: Administered subcutaneously near the affected area or target site for deeper tissue effects.
FORMULATIONS AND PRICING
| Medication | Formulation | Price |
|---|---|---|
| LL-37 | 5mg vial (1mg/mL x 5mL) | $135 |
| LL-37 / Thymosin Alpha-1 | 2mg-3mg/mL nasal spray (5mL) | $125 |
COMMON INITIAL DOSING REGIMENS
Topical: Applied to the affected area 1–2 times daily. Concentrations in topical formulations are often customized but typically range from 0.1% to 0.5%.
Injectable: A common protocol involves subcutaneous injections of 100–300 mcg daily or every other day for 2–4 weeks, depending on the condition treated. Maintenance dosing may be prescribed based on the response and clinical need.
MECHANISM OF ACTION
LL-37 exerts antimicrobial, immunomodulatory, and wound-healing effects. It disrupts bacterial membranes by forming pores, making it highly effective against Gram-positive and Gram-negative bacteria, fungi, and some viruses. LL-37 also modulates immune cell activity by suppressing pro-inflammatory cytokines (e.g., IL-6, TNF-α) and enhancing anti-inflammatory pathways.
In wound healing, LL-37 promotes angiogenesis and epithelialization by activating fibroblasts and keratinocytes. Its role in breaking down biofilms—a protective matrix formed by bacteria—makes it especially effective in treating chronic infections resistant to conventional antibiotics.
COMMON SIDE EFFECTS
Localized Reactions: Mild redness, swelling, or itching at the injection site.
Systemic Reactions: Transient fatigue, headache, or flu-like symptoms in rare cases.
Immune Effects: Overactivation of the immune system can cause exacerbation of autoimmune conditions in susceptible individuals.
Rare Effects: Allergic reactions, such as rash or difficulty breathing, though infrequent, should be monitored.
CONTRAINDICATIONS
Absolute: Hypersensitivity to LL-37 or any excipient.
Relative: Use with caution in patients with active autoimmune diseases, as LL-37 may exacerbate immune dysregulation. Limited safety data in pregnancy and breastfeeding advises against its use in these populations.
ADDITIONAL NOTES ON EFFICACY
LL-37 is a versatile peptide with applications extending beyond dermatology to systemic immune support and inflammation control. In hair restoration protocols, it is often paired with growth factors or other peptides like GHK-Cu to maximize follicular stimulation.
COMPARISON WITH THYMOSIN ALPHA-1
LL-37 and Thymosin Alpha-1 both modulate the immune system but differ in their primary mechanisms and applications. LL-37 focuses on antimicrobial effects and biofilm disruption, making it highly effective in infections and wound healing. Thymosin Alpha-1, on the other hand, boosts T-cell activity and immune regulation, with broader applications in viral infections, cancer immunotherapy, and vaccine enhancement.
While LL-37 directly combats pathogens, Thymosin Alpha-1 strengthens host defenses, particularly against chronic infections and immune suppression. Their complementary mechanisms may allow combined use in conditions involving both immune dysfunction and chronic infection.
MORE INFORMATION
FDA Safety Data Sheet not available (experimental peptide).